{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-092058","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2026-08-06T20:29:52+00:00","discovered_at":"2026-08-06T20:32:01.479685+00:00","generated_at":"2026-08-06T20:32:23.046896+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verastem Q2 net product revenue $25.1M; cash runway extended into H2 2027 via $75M Oberland deal","bullets":["Net product revenue of $25.1M from AVMAPKI FAKZYNJA CO-PACK, up from $2.1M in Q2 2025.","Total revenue $40.1M (incl. $15M COPIKTRA milestone); GAAP net loss $34.7M ($0.35/share).","Cash, equivalents & investments $136.4M; proforma $201.4M after $50M Oberland closing and $15M milestone.","First patients dosed in all three TARGET-D Phase 2 trials of VS-7375; updated data expected October 2026.","Appointed Michael P. Bailey to Board of Directors; non-dilutive royalty financing with Oberland Capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-092058","json":"https://secwatch.observer/filing/0001104659-26-092058.json","markdown":"https://secwatch.observer/filing/0001104659-26-092058.md","text":"https://secwatch.observer/filing/0001104659-26-092058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465926092058/0001104659-26-092058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465926092058/tm2622452d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:32:23.046896+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}